# HCW Biologics

Source: https://onco.cc/companies/hcw-biologics/  
OnCo record `hcw-biologics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

HCW Biologics is a Florida company making fusion proteins that act on the immune system, mainly for inflammatory diseases. For cancer, its lead product, HCW11-018b, is an injection under the skin that steers the body's T cells onto solid tumours and is being prepared for a first trial in people.

## Summary

HCW Biologics Inc., based in Miramar, Florida and listed on Nasdaq as HCWB, describes itself in its 2026 S-1 as a clinical-stage company developing fusion immunotherapeutics for diseases promoted by chronic inflammation, including autoimmune and proinflammatory diseases, cancer and senescence-associated dysplasia. Its founder and chief executive, Hing C. Wong, led the development of the IL-15 receptor agonist that was sold to ImmunityBio in 2017 and later approved for BCG-unresponsive non-muscle invasive bladder cancer.

In oncology, the filing names HCW11-018b, a tetravalent T-cell engager given by subcutaneous injection to treat solid tumours. After a Type B pre-IND meeting with the FDA in July 2026, the company says it is preparing an IND for a Phase 1 trial in solid tumours, to be filed in the first half of 2027. Its most advanced clinical compound is an IL-2 fusion protein complex in a Phase 1 trial in alopecia areata, and it has agreed to distribute a reagent molecule for cell therapy manufacturing through Akron Biotech.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: HCW Biologics Inc.
- HQ: Miramar, FL
- Type: biotech
- Website: https://hcwbiologics.com/
- Ticker: HCWB

## Notes

- Read from the S-1 filed on EDGAR on 2 October 2026 (prospectus summary and cover page) on 4 November 2026. Only the oncology programme is recorded as a product; the inflammation programmes are described without codes. Founding year not read.

## Sources

- SEC EDGAR: HCW Biologics S-1, October 2026: https://www.sec.gov/Archives/edgar/data/1828673/000149315226045532/forms-1.htm
- Official website: https://hcwbiologics.com/

## Connected records

- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/)
- drugs: [HCW11-018b](https://onco.cc/drugs/hcw11-018b/)

---
JSON: https://onco.cc/api/v1/entities/hcw-biologics.json